FIELD: clinical immunology. SUBSTANCE: invention relates to monoclonal antibody specifically immunoreactive to HIV-1 protein gp120 or gp160 which is characterized by being capable of in vitro neutralizing cells H9 by living strain of HIV-1. Antibodies are released by hybridon cell lines. Pharmaceutical compositions of invention can be used in treatment of HIV-1-infected patients by the aid of passive immunization. EFFECT: AIDS controlling method found. 16 cl, 39 dwg, 5 tbl, 10 ex
Authors
Dates
1999-08-20—Published
1993-08-24—Filed